BEAM-304

Gene therapy / editing

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

This drug's own stage for Phenylketonuria: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
BEAM-304: this drugStage not on recordGene therapy / editingPAH gene (phenylalanine hydroxylase)not yet gradedNo reviewed efficacy summary in this indication
Pegvaliase (PALYNZIQ)ApprovedProtein / enzyme therapeuticPhenylalanine ammonia lyase (enzyme substitution)Weak signalFeatured results are safety only in this race
Sapropterin Dihydrochloride (Kuvan)ApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signal
NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36)
NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009).
SepiapterinApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signalNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.